Eric Grossman, MD
Adult Reconstructive Orthopaedic Surgery · Harrison, NYNPI 1740484526
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,825 of the $75,965 with a category attached, or 61.6%. 19 manufacturers reported payments, led by Medacta USA, Inc. at 49.5% of the total. 2025 is the largest year on record at $33,662, more than ten times the $2,361 reported in 2019.
Across 167 payments — averaging $454.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medacta USA, Inc.$38K
- Medical Device Business Services, Inc.$12K
- Depuy Synthes Products, Inc.$11K
- Globus Medical$9K
- Stryker$3K
- Gotham Surgical Solutions & Devices, Inc.$1K
- plus $3K from 13 others
What the payments were for
- Consulting fees$46,82562%
- Travel & lodging$20,56927%
- Food & beverage$7,37210%
- Education$1,2002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medacta USA, Inc. | 65 | $37,599 |
| Medical Device Business Services, Inc. | 17 | $11,596 |
| Depuy Synthes Products, Inc. | 7 | $10,948 |
| Globus Medical | 14 | $8,738 |
| Stryker | 27 | $3,129 |
| Gotham Surgical Solutions & Devices, Inc. | 1 | $1,200 |
| Zimmer Biomet | 9 | $604 |
| Johnson & Johnson | 7 | $603 |
| Davol Inc. | 4 | $526 |
| Smith+Nephew | 2 | $263 |
| Conformis, Inc. | 1 | $220 |
| BD | 1 | $163 |
| Nevro Corp. | 1 | $111 |
| Medtronic(2 entities) | 3 | $80 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| Axogen | 2 | $47 |
| Bioventus LLC | 1 | $39 |
| Fujifilm New Development USA, Inc. | 1 | $34 |
| Covidien LP | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMISTEM$23,871
- AMIStem H Femoral Stems$2,964
- MAKO$2,183
- Legacy Stelkast Knee$1,881
- QUADRA$1,687
- ACTIS$1,528
- PROVIDENCE$1,425
- PROVIDENT HIP SYSTEM$1,250
- ATTUNE$1,230
- GMK SPHERE$1,088
- Velys$1,022
- ARISTA AH FLEXITIP$473
- NEXT AR$337
- iTotal Identity PS$220
- NextAR Platform$211
- NextAR Hip$198
- Avenir$190
- Quadra C Femoral Stems$166
- TRIATHLON$151
- PROGEL$143
How this compares
$75,965 in reported general payments places this provider in the 75th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.
See all adult reconstructive orthopaedic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 66 | $672 |
| Amoxicillin | 40 | $130 |
| Methylprednisolone | 16 | $96 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Harrison
- Seth JerabekNew York$7.1M
- Jose RodriguezNew York$3.4M
- Friedrich BoettnerNew York$2.9M
- Jonathan VigdorchikNew York$2.3M
- William LongNew York$1.5M
- Peter SculcoNew York$1.5M
- Roshan ShahNew York$1.3M
- Herbert CooperNew York$1.3M
- Matthew AustinNew York$986K
- Patrick MeereNew York$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.